Predicting the Future Subject\u27s Outcome via an Optimal Stratification Procedure with Baseline Information by Yong, Florence H. et al.
Harvard University
Harvard University Biostatistics Working Paper Series
Year  Paper 
Predicting the Future Subject’s Outcome via
an Optimal Stratification Procedure with
Baseline Information
Florence H. Yong∗ Lu Tian† Sheng Yu‡
Tianxi Cai∗∗ L. J. Wei††
∗Harvard University, florenceyong04@hotmail.com
†Stanford University, lutian@stanford.edu
‡Harvard University
∗∗Harvard University, tcai@hsph.harvard.edu
††Harvard University, wei@hsph.harvard.edu
This working paper is hosted by The Berkeley Electronic Press (bepress) and may not be commer-
cially reproduced without the permission of the copyright holder.
http://biostats.bepress.com/harvardbiostat/paper173
Copyright c©2014 by the authors.
Predicting the future subject’s outcome via an optimal
stratification procedure with baseline information
Florence H. Yong∗, Lu Tian†, Sheng Yu∗, Tianxi Cai∗, and LJ Wei∗
ABSTRACT
In predictive medicine, one generally utilizes the current study data to construct a stratifi-
cation procedure, which groups subjects with baseline information and forms stratum-specific
prevention or intervention strategies. A desirable stratification scheme would not only have a
small intra-stratum variation, but also have a “clinically meaningful” discriminatory capability
across strata to avoid unstable and overly sparse categorization. We show how to obtain an opti-
mal stratification strategy with such desirable properties from a collection of candidate models.
Specifically, we fit the data with a set of regression models relating the outcome to its baseline
covariates. For each fitted model, we create a scoring system for predicting potential outcomes
and obtain the corresponding optimal stratification rule. Then, all the resulting stratification s-
trategies are evaluated with an independent dataset to select a final stratification system. Lastly,
we obtain the inferential results of this selected stratification scheme with a third independent
holdout dataset. If there is only one current study data available and the study size is moder-
ate, we combine the first two steps via a conventional cross-validation process. We illustrate
the new proposal using an AIDS clinical trial study for binary outcome and a cardiovascular
clinical study for censored event time outcome.
KEY WORDS: Cox regression model; Cross-validation; Dynamic programming; Prediction
score; Stratified medicine
1. INTRODUCTION
To construct a prediction procedure for the future subject’s outcome via its baseline information,
a common practice at the first step is to fit the current data with a parametric or semi-parametric
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regression model, which relates the subject’s outcome to its covariates. If the model is a reasonable
approximation to the true one, the resulting individual predicted value would be close to its outcome
value. Such predicted values create a scoring system for all future subjects. In practice, one then
groups the scores into several strata and uses the average of observed outcome values in one stratum
to predict outcomes from new subjects classified into the same stratum for making targeted preven-
tion or intervention. A desirable stratification scheme would have a small intra-stratum variation and
a clinically meaningful discriminatory capability to avoid unstable and overly sparse groupings. To
the best of our knowledge, there are no systematic approaches one can take to construct an optimal
stratification with such desirable features.
As an example to illustrate the current practice in stratified medicine, we utilize the data from
a clinical study for treating HIV diseases (Hammer et al., 1997). This trial (ACTG 320) was a
randomized, double-blind, placebo-controlled clinical study conducted by the AIDS Clinical Trials
Group. It successfully demonstrated the overall efficacy of a combination of two nucleoside regimen
with a protease inhibitor Indinavir for treating HIV-infected patients. The combination treatmen-
t concept has since been well adopted for the current HIV patient’s management. However, this
particular combination therapy may not work well for all patients from risk-cost-benefit perspec-
tives. Here, we show a conventional, ad hoc procedure to construct a stratification scheme using
the patients’ baseline variables. For this study, there were 537 patients treated by the three drug
combination who had complete baseline information. One of the endpoints was a binary outcome
Y, indicating whether the patient’s HIV-RNA viral level was under an assay detectable level (500
copies/mL) at week 24 or not. A non-responder to the treatment was defined as the RNA level being
above 500 copies/mL at week 24 or an informative dropout before week 24 due to treatment failure.
The observed overall response rate was 45%. To build a predictive scoring system, for illustration,
let us consider a rather simple additive logistic regression model for Y with four baseline covari-
ates: age, sex (female=1, male=0), CD4 count (CD40), and the log10 of HIV-RNA (log10 RNA0).
The numerical RNA level is used and all log10 RNA0 measures below log10(500) are replaced by
0.5 log10(500) = 1.35 in our analysis. We then fit the entire dataset with the model and the resulting
individual predicted response rate is:
ψ(−0.508 + 0.044age− 0.493sex + 0.004CD40 − 0.346 log10 RNA0), (1.1)
2
http://biostats.bepress.com/harvardbiostat/paper173
where ψ(s) = {1 + exp(−s)}−1 is the anti-logit function. The 537 predicted response rates range
from 0.09 to 0.93. If the model is reasonably good, a future subject with a high score tends to
respond to the treatment. A conventional way to group those patients is to stratify them into, for
instance, four consecutive categories with roughly equal sizes by using the quartiles of the predicted
scores. The empirical average response rates for these strata are 31%, 42%, 38%, and 67%, respec-
tively. Unfortunately this ad hoc stratification scheme does not have discriminatory capability across
all the strata. The average response rates are not monotonically increasing over the ordered strata,
potentially due to the inadequate prediction model (1.1) or an improper grouping of the prediction
scores.
In this article, we present an optimal and systematic stratification strategy incorporating model
selection from a collection of candidates which satisfy certain clinically meaningful criteria. Specif-
ically, in Section 2, we show how to obtain an optimal grouping scheme for each candidate scoring
system created from a regression model. For example, with the predicted response rates (1.1), we
consider all possible discretization schemes, whose stratum sizes would be at least 10% of the study
sample size and any two consecutive stratum-specific average response rates are monotonically in-
creasing with an incremental value of at least 20% to ensure a discrimination capability for future
population. We then choose the best stratification, which minimizes a certain overall prediction
error (2.2) among all the possible stratification schemes with such desirable features. Dynamic pro-
gramming techniques are utilized to solve this nontrival optimization problem. With the data from
the HIV example and model (1.1), this results in three categories with the stratum-specific average
response rates of 11%, 42% and 69% and stratum sizes of 65, 343, and 129, respectively. Note
that if model (1.1) is appropriate, future patients classified to the first stratum may not benefit much
from this rather costly three-drug combination therapy especially for regions where the resource is
limited.
In Section 3, we consider a collection of candidate scoring systems and utilize the method in Sec-
tion 2 to obtain the optimal stratification for each scoring system. To avoid the overfitting problem,
we then use an independent dataset to evaluate all the resulting stratification schemes with respect to
a clinically interpretable prediction error measure, which also quantifies the within-stratum hetero-
geneity, to select the final stratification scheme. The last step is to make inferences for the selected
prediction procedure using a third independent dataset. If the data are from a single study with a
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moderate size, one may combine the model building and evaluation processes via a cross-validation
procedure. In Section 4, we generalize the new proposal to handle censored event time outcomes and
illustrate the procedure using the data from a recent cardiovascular study (Braunwald et al., 2004)
in Section 5. We conclude with additional observations and potential generalizations in Section 6.
2. AN OPTIMAL STRATIFICATION PROCEDURE FOR A SPECIFIC SCORING
SYSTEM
In this section, we show how to obtain an optimal grouping system from a single working model
such as (1.1). Let Y be the outcome variable and V be a vector of “baseline” covariates. Assume
that the conditional mean µ(V ) = E(Y |V ) is the parameter of interest for future prediction. To
estimate µ(V ) when the dimension of V is more than one, we generally use a working model which
relates Y to Z, a function of V . For example, µ(V ) = g(β′Z), where g(·) is a given smooth
monotone function. Let the data consist of n independent copies {(Yi, Vi, Zi), i = 1, · · · , n} of
(Y, V, Z). An estimate βˆ for β can be obtained via a regularized estimation procedure, for example,
the least absolute shrinkage and selection operator (lasso) (Tibshirani, 1996), especially when the
dimension of Z is large. If the regression model is a reasonable approximation to the true one,
the resulting estimator µˆ(V ) = g(βˆ′Z) would be close to µ(V ), and a large µˆ(·) indicates that the
subject would have a large outcome value Y .
As an example, for the binary outcome Y in the HIV study discussed in the Introduction, one may
use a logistic model with lasso or ridge regularization to obtain µˆ(·). Here, the regression parameter
estimate βˆ is obtained by minimizing the loss function
− log{L(β)}+ λ‖β‖pp, (2.1)
where L(β) is the likelihood function, λ is the tuning (penalty) parameter and ‖β‖pp is the pth power
of the Lp norm for the vector β. The (2.1) results in the standard lasso and ridge regression with
p = 1 and 2, respectively. The score (1.1) in the Introduction gives the individual predicted response
rate based on the simple additive logistic regression with four baseline covariates and λ = 0.
Suppose that we group n subjects into K consecutive strata S1, S2, · · · , SK based on the score
µˆ(·). Let Y¯k be the empirical mean of Yi’s in the kth stratum, k = 1, · · · ,K. For a future sub-
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ject being classified to the kth stratum, we predict the individual outcome with the corresponding
stratum-specific mean Y¯k. To evaluate the performance of this stratification, one may consider a
loss function:
1
n
K∑
k=1
∑
i∈Sk
|Yi − Y¯k|, (2.2)
which also quantifies the average within stratum variation. When all the scores are distinct, an
optimal stratification, which minimizes (2.2), would result in n strata with only one member in
each stratum and the observed prediction error is zero. However, the prediction error for future
observations with such an overly sparse stratification would be unacceptably high. To increase the
prediction precision while ensuring stable subgroups, one may group the subjects with a minimal
stratum size of at least a certain fraction p0 of the sample size n. Moreover, to ensure that the strati-
fication scheme has a clinically meaningful discriminatory capability, namely, yielding meaningful
differences in group-specific average outcomes between subgroups, we further impose a constraint
for all candidate stratification schemes such that
Y¯k − Y¯k−1 ≥ d; for k = 2, · · · ,K, (2.3)
where d is a given positive value, representing the minimum clinically meaningful increment.
Consider all possible stratifications which satisfy (2.3) with a minimum stratum size fraction of
at least p0. To obtain an optimal stratification scheme by minimizing (2.2) is a rather challenging
problem. In Appendix A, we show how to identify the boundary values {cˆ0, cˆ1, · · · , cˆK−1, cˆK}
of the consecutive strata via dynamic programming (Taha, 2003), that is, Sk = {i | cˆk−1 <
µˆ(Vi) ≤ cˆk, i = 1, · · · , n}, k = 1, 2, · · · ,K. Without loss of generality, here we assume that
cˆ0 = −∞ and cˆK = ∞. Note that we use L1 norm (2.2) to evaluate the prediction error,
which is more heuristically interpretable than, for example, the one with the L2 norm. Further-
more, if the regularized estimator βˆ of the working regression model converges to a constan-
t vector β0 and the resulting score estimate µˆ(v) converges to a deterministic function µ˜(v) for
all v, the above empirical optimal stratification scheme, in the limit, minimizes, with respect to
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c = {−∞ = c0 < c1 < · · · < cK−1 < cK =∞}, the limit of (2.2):
L(c) = E
∣∣Y − f(V |c)∣∣ subject to

pr(ck−1 < µ˜(V ) ≤ ck) ≥ p0
µ¯k − µ¯k−1 ≥ d
, (2.4)
where
f(V |c) =
K∑
k=1
I(ck−1 < µ˜(V ) ≤ ck)µ¯k,
I(·) is the indicator function and µ¯k = E(Y | ck−1 < µ˜(V ) ≤ ck). The justification of this asymp-
totic property is given in Appendix B. Note that using the lasso regularized estimation procedure,
the estimators βˆ and µˆ(·) are stabilized asymptotically. This large sample property of the optimal
stratification scheme is essential to ensure its stability under the cross-validation setting discussed
in Section 3.
3. SELECTING AN OPTIMAL STRATIFICATION SCHEME FROM A COLLECTION
OF COMPETING SCORE SYSTEMS
For a prediction score system created by a given working regression model, one can obtain its
optimal stratified prediction procedure as presented in Section 2. To make inferences about the re-
sulting stratified prediction procedure, for instance, constructing a valid confidence interval estimate
for the mean response value of each stratum, one may utilize an independent dataset to avoid overly
optimistic inferential conclusions. To this end, with data from a single study, we may split the data
into two independent parts, say, I and II. Using the data from Part I, we obtain the optimal strati-
fication scheme. Then we use the data from Part II to make inferences for prediction. Moreover,
if there is a collection of competing stratified score systems considered as potential candidates, we
further split the data from Part I into two independent parts, say, Ia and Ib. The data from Part Ia are
used for obtaining the optimal stratification schemes for each candidate scoring system as we did
in Section 2, whereas data from Part Ib are used for evaluating all candidates and selecting the best
stratification scheme.
Suppose that there are several optimal stratification schemes available with the data from Part Ia.
In this section, we show how to evaluate them and choose the “best” one. Let the data from Part Ib
be denoted by n∗ independent identically distributed observations {(Y ∗i , V ∗i , Z∗i ), i = 1, · · · , n∗},
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where a generic variable “A∗” is defined as “A” in Section 2. For each candidate scoring sys-
tem, we obtain its optimal stratified counterpart from the data of Part Ia with boundary points
{cˆ0, cˆ1, · · · , cˆK} and the stratum-specific prediction values {Y¯k, k = 1, · · · ,K}. To evaluate the
predictive performance of such a stratification scheme with the data from Part Ib, we consider the
following loss function, reflecting the within-stratum variation for the prediction accuracy:
L∗ = 1
n∗
K∑
k=1
∑
µˆ(V ∗i )∈(cˆk−1,cˆk]
|Y ∗i − Y¯k|, (3.1).
where n∗ =
∑K
k=1 n
∗
k and µˆ(V
∗
i ) = g(βˆ
′Z∗i ). An optimal stratification scheme is chosen which
minimizes (3.1) among all the candidates under consideration. On the other hand, a parsimonious
model may be appealing in practice if its (3.1) is greater than but still comparable to the minimum
value of (3.1) derived from a complex model.
Now, since the sizes of Parts Ia and Ib may be small, one may use the Monte-Carlo cross-
validation (MCCV) method (Xu and Liang, 2001; Yong et al., 2013) to obtain a more stable (3.1).
Specifically, we randomly split Part I dataset into Ia and Ib, say,N times. For the jth split, we repeat
the above model building and evaluation procedure for each candidate model and obtain L∗j from
(3.1). We then compute the average, L¯∗ = N−1∑Nj=1 L∗j . For each candidate model, we refit the
entire Part I data and let the final realized stratification rule be denoted byM∗. The pair (L¯∗,M∗)
reflects the magnitude of the estimated within-stratum variation and the model complexity of each
candidate. The selection of an “optimal” stratification rule would be based on such pairs. With the
data from Part II, we then construct confidence interval estimates for the stratum-specific mean val-
ues of the outcome variables for the final selected stratification scheme. It is important to note that
the lasso regularized regression coefficient estimate is stabilized asymptotically for each regression
model fitting in the above cross-validation process. It follows that for each candidate regression
model, the final refitted stratification scheme would minimize (2.4) in the limit.
We now use the data from the HIV study to illustrate our proposal. For this study, other than
the four baseline variables discussed in the Introduction, there are seven baseline covariates and
two short-term marker values at week 4 including CD4 count (CD44) and log10 RNA (log10 RNA4),
which may be relevant to the outcome and have potential predictive values. The additional baseline
covariates are race (non-Hispanic White, African American, other), injection-drug use, hemophilia,
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CD8 count, weight, Karnofsky performance score, and months of prior zidovudine therapy. There
are very few missing covariate values. Any missing covariates are replaced by their corresponding
sample averages from the observed counterparts.
In our analysis, we first randomly split the entire dataset of 537 patients into Part I and Part II
evenly with sample sizes of 268 and 269, respectively. The number N of the MCCV is 200 and
the sizes of Part Ia and Ib are equal for each cross-validation. For illustration, we consider four
different working models in which the first three are various logistic regression models with lasso
regularization methods and tuning parameters selected via a 20-fold cross-validation procedure built
in the R package glmnet (Friedman et al., 2010). The fourth model is a null model using the
overall mean response proportion in Part Ia to predict future outcomes for each cross-validation run.
Table 1 summarizes the composition of each model. We also present L¯∗ obtained by averaging
the 200 L∗j values; and for the corresponding M∗, we report its number of informative baseline
covariates needed for computing the score µˆ(V ) and number of nonzero regression coefficients
in βˆ to summarize its complexity. Note that for all candidate stratification schemes, we use the
incremental value of d = 0.2 and the minimum stratum size fraction of p0 = 0.1 in the Part Ia
training data.
From Table 1, Models 1 and 3 have almost the same L¯∗ values, but theM∗ of Model 1 has fewer
baseline covariates involved and the resulting predicted response rate is
ψ(−0.231− 0.075 log10 RNA0− 0.459 log10 RNA4 + 0.00036CD40 + 0.0028CD44 + 0.0288age).
With this final selected stratification schemeM∗, there are three strata whose cˆ1 = 0.25 and cˆ2 =
0.45. The stratum-specific means and numbers of observations are 0.06 (n = 51), 0.36 (n = 107),
and 0.62 (n = 110), respectively. Note that these stratum-outcome-average estimates may be biased
due to the extensive model building, evaluation and selection. To obtain valid inferences for this final
prediction procedure, we use the above stratification boundary values cˆ1 and cˆ2 to group subjects
from Part II. The resulting point and 0.95 confidence interval estimates for the three stratum-average
response rates are 0.17 (0.06, 0.28), 0.41 (0.31, 0.51) and 0.65 (0.57, 0.73), with stratum size n =
47, 91, and 131 respectively as displayed in Figure 1. Note that the above inferential results would
be a valid and final assessment on the practical value of this prediction scheme.
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4. GENERALIZATION TO CASES WITH EVENT TIME AS THE OUTCOME
VARIABLE
If the outcome T is the time to a specific event, potentially this variable T may be censored and
the mean or median value of the outcome variable cannot be estimated well. A common summary
parameter of interest is the event rate at a specific time point τ . However, this measure does not
include information about the event occurrence profile. On the other hand, the restricted mean
survival time (RMST) is a clinically meaningful summary for such a distribution (Royston, 2009;
Royston and Parmar, 2011; Zhao et al., 2013). Specifically, let Y = TI(T ≤ τ) + τI(T > τ) and
µ(V ) = E(Y |V ) = ∫ τ0 S(t|V )dt as defined in Section 2, where S(t|V ) = pr(T > t | V ). Here,
µ(V ) is the average event-free time for all subjects with covariate V , which would be followed up
to time point τ . Often, the outcome T (and Y ) may be right censored by an independent random
variable C. However, one can always observe (X,V,∆), where X = min(T,C) and ∆ is a binary
variable, which is one if X = T and zero otherwise. Therefore, the observed data consist of
n independent copies {(Xi, Vi,∆i), i = 1, · · · , n} of (X,V,∆). Note that Yi = min(Ti, τ) is
observed when ∆i = 1 or Ti ≥ τ .
Inferences about µ(V ) under the one- and two-sample and regression settings have been exten-
sively studied (Zucker, 1998; Tian et al., 2013). For example, to estimate the RMST for a single
group, the area under the Kaplan-Meier curve is a nonparametric consistent estimator. To create a
scoring system for µ(V ), one may use the Cox (1972) procedure to model the relationship between
the survival function S(t|V ) of the event time and its covariates V :
log{− logS(t|V )} = log{− logS0(t)}+ β′Z,
where S0(·) is an unknown baseline survival function, and β is the regression coefficient vector. A
regularized estimate βˆ of β can be obtained by minimizing
− log(PL(β)) + λ‖β‖pp,
where PL(·) is the partial likelihood function. The S0(t) can then be estimated by exp{−Λˆ0(t)},
where Λˆ0(t) is the Breslow estimate for the underlying cumulative hazard function (Breslow, 1972).
9
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It follows that the RMST for subjects with the covariate V can be estimated as
µˆ(V ) =
∫ τ
0
exp{−Λˆ0(t)eβˆ′Z}dt.
For any scoring system, we can then use the same technique described in section 3 to obtain an
optimal stratification scheme. Specifically, in the limit, we are interested in minimizing (2.4). As-
suming that the censoring time is independent of the survival time T and covariates V, the prediction
error in (2.4) can be estimated as
n−1
K∑
k=1
∑
i∈Sk
wi|Yi − Y¯k|,
where wi = {∆i + (1 − ∆i)I(Ti ≥ τ)}/Gˆ(Yi) and Gˆ(·) is the Kaplan-Meier estimate for the
censoring distribution using the entire dataset (Part I and II). Here, Y¯k is a consistent estimator for
the kth stratum-specific RMST, which is the weighted average
∑
i∈Sk wiYi∑
i∈Sk wi
.
With the same constraints as described in Section 2, an optimal stratification can be obtained via
the dynamic programming technique given in Appendix A. If the estimated RMST converges to a
deterministic limit as the sample size increases, it follows from a similar argument in Appendix B,
the finite sample stratified scheme would have the same asymptotic property as that for the non-
censored case.
To select the “best” scoring model from the competing scoring systems, one can utilize the proce-
dure in Section 3 with the weighted version of (3.1) to evaluate the candidate stratification schemes
via the cross-validation using the data from Part Ia and Ib iteratively. The inference of the prediction
procedure with the final selected model can then be made accordingly with the data from Part II.
5. AN ILLUSTRATIVE EXAMPLEWITH CENSORED EVENT TIME OUTCOMES
We use the data from a cardiovascular clinical trial “Prevention of Events with Angiotensin Con-
verting Enzyme Inhibition” (PEACE) to illustrate the proposal with an event time outcome variable.
The PEACE trial is a double-blind, placebo-controlled study (Braunwald et al., 2004) of 8290 pa-
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tients enrolled to investigate if the addition of an Angiotensin-converting-enzyme (ACE) inhibitor
therapy trandolapril at a target dose of 4 mg/day to the conventional therapy would provide benefit
with respect to, for example, the patient’s specific cardiovascular event-free survival. For illustra-
tion of our proposal, the outcome variable is assumed to be the time to death, nonfatal myocardial
infarction or coronary revascularization, whichever occurred first. There are 2110 patients (25%),
who experienced this composite event with the median follow-up time of 54 months. The 0.95
confidence interval estimate for the hazard ratio is (0.86, 1.02) with a p-value of 0.15 based on
the logrank test. Since there was no statistically significant treatment effect, we combined the data
from the two treatment groups for our illustration. The Kaplan-Meier curve for the entire dataset
is given in Figure 2. The overall observed event times in months range between 0.1 and 81.5 with
an interquartile range of 12.8 and 42.4. If we let τ = 72 (months), the estimated restricted mean
event time for the entire group is 60.4 months. This suggests that for future patients in this study
population, one expects to have an average of 60.4 months event-free with a follow-up time of 72
months.
Based on the results by Solomon et al. (2006), we considered the following baseline covariates
for prediction: the study treatment indicator, age, gender, left ventricular ejection fraction, history
of myocardial infarction, history of hypertension, history of diabetes, and estimated glomerular
filtration rate as a 4-category discretized version represented by 3 indicator variables eGFR1, eGFR2
and eGFR3 with cut-points of 45, 60, and 75. We imputed the missing covariate values with their
corresponding sample mean counterparts for continuous variables and the most frequently observed
category for binary variables. We then randomly split the data evenly into Parts I and II with 4145
patients each. Moreover, for Part I data, we randomly split it evenly for the cross-validation process
with 200 iterations. Several candidate models are considered and listed in Table 2. Note that Model
2 is built upon the observation that there is potential treatment and eGFR interaction reported by
Solomon et al. (2006).
For each regression candidate model, we use the incremental value of d = 3 months and the min-
imum stratum fraction of p0 = 0.1. Table 2 summarizes the L¯∗ for the optimal stratification based
on each regression working model as well as the numbers of informative baseline covariates used in
computing the estimated scores and nonzero regression coefficients of βˆ forM∗. Model 2 has the
smallest L¯∗ and yields three strata with cutoff points cˆ1 = 56.5 and cˆ2 = 60.5 months. The range of
11
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estimated RMST is from 51.0 to 63.8 months in Part I dataset. The corresponding estimated RMSTs
for three strata are 54.5, 58.7 and 62.3 months, respectively. To make inferences about the predic-
tion of this selected final stratification scheme, we apply it to the Part II data. The corresponding
Kaplan-Meier curves for three strata are given in Figure 3. Based on the restricted area under the
Kaplan-Meier curves derived from 1000 bootstrap samples, the point and 0.95 confidence interval
estimates for the stratum-specific restricted mean survival times are 54.3 (51.0, 57.2), 58.9 (57.7,
60.0) and 62.0 (61.2, 62.8) months, for the three strata with n = 245, 1350, and 2550 respectively.
6. REMARKS
A common practice in predictive medicine is to create an ordered category system to classify
future subjects with their “baseline” information. A desirable quantitative stratification procedure
would have both a small overall prediction error and a reasonable discriminatory capability across
the strata. In this article, we provide a systematic approach to construct such a stratification rule. To
achieve the first goal, we utilize a heuristically interpretable metric (a loss function based on the L1
norm) for quantifying the prediction error. Moreover, the stratification requires a minimum size of
the stratum to avoid having unstable small strata. The choice of the minimum size does not have a
rigorous rule. It depends on the amount of “information” of the training set Part Ia, which is usually
quantified by the sample size or the observed event rate. To enhance the discriminatory ability of
the scheme, we set a minimum incremental value between two consecutive stratum-specific predict
values at the model building stage. The choice of this value depends on clinical inputs. For example,
for the cardiovascular study, the range of the RMST scores is from 51.0 to 63.8 (months) based on
the Part I training data, which is relatively narrow. A choice of an incremental value of 3 months
for illustration in Section 5 seems appropriate.
An obvious extension of the new proposal is to construct an optimal stratification procedure for
treatment selections based on data either from randomized clinical trials or observational studies.
Unfortunately, the L1 loss function utilized in this article cannot be trivially generalized to deal
with this important problem. Further research on the choice of a clinically meaningful metric for
quantifying the prediction error for treatment selections is warranted.
12
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APPENDIX A: THE DYNAMIC PROGRAMMING ALGORITHM FOR OPTIMAL
STRATIFICATION
We will describe the dynamic programming algorithm for identifying the optimal grouping in this
section. Below we first provide a brief introduction to the dynamic programming algorithm. To this
end, assume that our objective is to find the minimum total cost of n stages:
min
{at}
n∑
t=1
ct(st, at),
where st is the state of stage t, at ∈ At(st) is the action we take at stage t, and ct(st, at) is the cost
associated with state st and action at. The state of the next stage st+1 is determined by both st and
at: st+1 = ft(st, at), t = 1, . . . , n − 1. If we know that the minimum total cost from stage m + 1
through stage n starting at state sm+1 is
Cm+1(sm+1) = min{at}
n∑
t=m+1
ct(st, at),
then the optimal cost from stage m starting at state sm is simply
Cm(sm) = min
am∈Am(sm)
{cm(sm, am) + Cm+1(fm(sm, am))} .
Thus we can start from the minimum cost Cn(sn) = minan cn(sn, an) at stage n to consecutively
find the optimal solutions at stages n− 1, n− 2, · · · , 2 and 1.
Our problem is more complicated than the formulation above due to the presence of constraints,
but the basic principle remains the same. Without loss of generality, we assume that the data consists
of {(Yi, wi, µˆ(Vi)), i = 1, 2, · · · , n}, with µˆ(V1) < µˆ(V2) < · · · < µˆ(Vn). Here Yi and wi are
response and associated nonnegative weight for the ith observation. The objective is to group n
observations into K strata: Sk, k = 1, · · · ,K, such that
K∑
k=1
∑
i∈Sk
|Yi − Y¯ (Sk)|wi,
13
Hosted by The Berkeley Electronic Press
is minimized under the constraints that
nk ≥ np0 and Y¯ (Sk)− Y¯ (Sk−1) ≥ d,
where p0 is the minimum stratum fraction, Si denotes the set of observations in the ith stratum: S1 =
{1, 2, · · · , n1}, Sk =
{∑(k−1)
j=1 nj + 1,
∑(k−1)
j=1 nj + 2, · · · ,
∑(k−1)
j=1 nj + nk
}
, k = 2, · · · ,K and
Y¯ (S) =
∑
i∈S wiYi∑
i∈S wi
, for S ⊂ {1, · · · , n}.
Here d and p0 are given a priori but K is unknown. To this end, we consider the optimal grouping
for the last m observations {n − m + 1, n − m + 2, · · · , n} with the first stratum Smj1 com-
prised of j observations, where m ≥ np0. That is, Smj1 = {n−m+ 1, · · · , n−m+n1}, Smjk ={
n−m+∑(k−1)j=1 nj + 1, n−m+∑(k−1)j=1 nj + 2, · · · , n−m+∑(k−1)j=1 nj + nk} , k = 2, · · · ,Km
minimizes
Km∑
k=1
∑
i∈Smjk
|Yi − Y¯ (Smjk)|wi,
under the constraints that n1 = j,
nmjk ≥ np0 and Y¯ (Smjk)− Y¯ (Smj(k−1)) ≥ d.
Here j = 1, 2, · · · ,m. Let Lmj be the minimum L1 loss for grouping the lastm observations with j
observations in the first stratum under the constraint above. Let the corresponding optimal grouping
Smj1, · · · , SmjKm be denoted by Gmj . If there is no stratification satisfying the constraints, e.g.,
when j < np0, then Lmj = +∞. In such a case, we let Gmj = φ for convenience in notations.
Also, denote Y¯ (Smj1) by Y¯mj .
Like the standard dynamic programming algorithm, we start from the last observation and (G11, L11)
can be obtained easily since (G11, L11) = ({n}, 0) if 1 ≥ np0 and (φ,+∞) otherwise. Assume that
14
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for 1 ≤ m < n we have obtained
(G11, L11, Y¯11)
(G21, L21, Y¯21) (G22, L22, Y¯22)
(G31, L31, Y¯31) (G32, L32, Y¯32) (G33, L33, Y¯33)
· · ·
(Gm1, Lm1, Y¯m1) (Gm2, Lm2, Y¯m2) · · · (Gmm, Lmm, Y¯mm).
We can construct {G(m+1)j , L(m+1)j} based on the previous set of optimal solutions as follows. If
j < np0, then
(G(m+1)j , L(m+1)j) = {φ,+∞}.
For np0 ≤ j ≤ m + 1, since the first stratum of size j is fixed, we should choose the optimal
grouping strategy that minimizes the loss of the remaining m+ 1− j observations. To examine the
minimum incremental constraint between consecutive groups, we need and only need to consider
the first two strata. Let i be the number of members of the second group, i.e., the group after the
first j observations, we may define
i∗ = arg min
i
cj(i), i = 1, · · · ,m+ 1− j
where
cj(i) =

∑n−m−1+j
i=n−m |Yi − Y¯(m+1)j |wi + L(m+1−j)i if Y¯(m+1)j − Y¯(m+1−j)i ≥ d
∞ if Y¯(m+1)j − Y¯(m+1−j)i < d
.
This step of finding i∗ is not difficult since it involves onlyO(m+1− j) summations. However, we
can further simplify the computation by keeping the ranks of {Ll1, Ll2, · · · , Lll} for all l ≤ m. To
identify i∗, we only need to examine the constraint of the grouping with the smallest L(m+1−j)i :
Y¯(m+1)j − Y¯(m+1−j)i ≥ d. If the constraint is satisfied, then i∗ is identified, otherwise we examine
the constraint of the grouping with the second smallest L(m+1−j)i and et al. Normally, we can find
i∗ well before exhausting all L(m+1−j)i. Once i∗ is identified, L(m+1)j = cj(i∗) and if L(m+1)j <
∞, G(m+1)j = {S(m+1)j1} ∪ G(m+1−j)i∗ . Therefore, one may construct (G(m+1)j , L(m+1)j), j =
15
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1, 2, · · · ,m+ 1 by tracking (Gm˜j˜ , Lm˜j˜), 1 ≤ m˜ ≤ m and 1 ≤ j˜ ≤ m˜, for m = 1, 2, · · · , n− 1. In
the end, once (Gnj , Lnj), j = 1, · · · , n are obtained, the optimal stratification is simply Gnj∗ , where
j∗ = arg min
j
Lnj , j = 1, 2, · · · , n.
The complexity of the algorithm is O(n3) and therefore the computation can be slow when n is
big. In such a case, one may pre-group observations with similar µˆ(Vi)s together before applying
the dynamic programming. One way to achieve this is to divide the interval containing all the esti-
mated scores into subintervals and represent all the µˆ(Vi)s in the same subinterval by its center. In
this way, we effectively reduce the choices of potential grouping while using the original Yis and
wis to calculate the Y¯k and prediction error. The computation speed can be substantially improved
without sacrificing much precision in locating the optimal stratification scheme.
APPENDIX B: ASYMPTOTIC PROPERTIES FOR THE OPTIMAL STRATIFICATION
SCHEME
We first assume that βˆ − β0 = op(1) for properly chosen λ, where β0 belongs to a compact set,
the parameter space of interest. Without loss of generality, we also assume that the score µ(Vi) is a
continuous random variable with a bounded support and the joint density function of the continuous
components of (Yi, Vi) is continuously differentiable. Furthermore, we assume that the outcome Yi
is bounded. Let
Ln(c) = n
−1
n∑
i=1
|Yi − f(Vi|c)
∣∣
and
L(c) = E|Yi − f0(Vi|c)
∣∣,
where c = (−∞ = c1 < c2 < · · · < cK =∞)′, µˆ(Vi) = g(βˆ′Zi), µ(Vi) = g(β′0Zi),
f(Vi|c) =
K∑
k=1
µˆY (ck−1, ck)I(µˆ(Vi) ∈ (ck−1, ck]),
f0(Vi|c) =
K∑
k=1
µY (ck−1, ck)I(µ(Vi) ∈ (ck−1, ck])
µˆY (a, b) =
n−1
∑n
i=1 YiI(µˆ(Vi) ∈ (a, b])
n−1
∑n
i=1 I(µˆ(Vi) ∈ (a, b])
and µY (a, b) = E(Y |µ(Vi) ∈ (a, b]).
16
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Firstly, we will show that
sup
c
|Ln(c)− L(c)| = op(1),
where the sup is over all c such that pr(µ(Vi) ∈ (ck−1, ck]) ≥ δ0 > 0. Since K is bounded and
takes only finite number of possible values, it is sufficient to show the above uniform convergence
for fixed any fixed K. To this end, we note that the coverage number N[](,F , L1) < ∞ for the
class of functions F = {yI(g(β′z) ∈ (a, b]) | max(|a|, |b|, ‖β‖1) < C0} or {I(g(β′z) ∈ (a, b]) |
max(|a|, |b|, ‖β‖1) < C0}, whereC0 <∞ is a constant. Thus it follows from the Glivenko-Cantelli
theorem that
sup
max{|a|,|b|,‖β‖1}<C0
∣∣∣∣ n−1 n∑
i=1
YiI(g(β
′Zi) ∈ (a, b])− E
{
YiI(g(β
′Zi) ∈ (a, b])
} ∣∣∣∣= op(1)
and
sup
max{|a|,|b|,‖β‖1}<C0
∣∣∣∣ n−1 n∑
i=1
I(g(β′Zi) ∈ (a, b])− pr(g(β′Zi) ∈ (a, b])
∣∣∣∣= op(1),
which implies that
sup
(a,b,β)∈Ω0
∣∣∣∣ n−1∑ni=1 YiI(gˆ(β′Zi) ∈ (a, b])n−1∑ni=1 I(gˆ(β′Zi) ∈ (a, b]) − E(Y |g(β′Zi) ∈ (a, b])
∣∣∣∣= op(1), (B.1)
where Ω0 = {a, b, β | pr(g(β′Zi) ∈ (a, b]) ≥ δ0,max{|a|, |b|, ‖β‖1} < C0}. Next, consider
Un(a, b, β) = n
−1
n∑
i=1
I(g(β′Zi) ∈ (a, b])
∣∣∣∣ Yi − n−1∑ni=1 YiI(g(β′Zi) ∈ (a, b])n−1∑ni=1 I(g(β′Zi) ∈ (a, b])
∣∣∣∣ .
It follows from (B.1) that
sup
(a,b,β)∈Ω0
∣∣∣∣ Un(a, b, β)− n−1 n∑
i=1
I(g(β′Zi) ∈ (a, b])
∣∣Yi − E(Y |g(β′Zi) ∈ (a, b])∣∣ ∣∣∣∣= op(1).
Now, consider the class of functions F = {I(g(β′v) ∈ (a, b])|y − µ˜(a, b, β)| | (a, b, β) ∈ Ω0},
where µ˜(a, b, β) has continuous partial derivatives with respect to a, b and β. The covering number
17
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of the class is finite as well, and it follows from the Glivenko-Cantelli theorem that
n−1
n∑
i=1
I(g(β′Zi) ∈ (a, b])
∣∣Yi − E(Y |g(β′Zi) ∈ (a, b])∣∣
uniformly converges to u(a, b, β) = E
{
I(g(β′Zi) ∈ (a, b])
∣∣Yi − E(Y |g(β′Zi) ∈ (a, b])∣∣} over the
set Ω0 and thus
sup
(a,b,β)∈Ω0
∣∣∣∣ Un(a, b, β)− u(a, b, β) ∣∣∣∣= op(1).
Coupled with the fact that u(a, b, βˆ)− u(a, b, β0) = op(1), it suggests that
sup
(a,b,β)∈Ω0
∣∣∣∣ Un(a, b, βˆ)− u(a, b, β0) ∣∣∣∣= op(1).
Now, note the fact that
Ln(c) =
K∑
k=1
Un(ck−1, ck, βˆ) and L(c) =
K∑
k=1
u(ck−1, ck, β0),
we have
sup
c
∣∣∣∣ Ln(c)− L(c) ∣∣∣∣= op(1).
Secondly, we will derive the upper bound of L(cˆ) as n → ∞. To this end, let the constraint be
written as Sn(c) ≥ 0, where
Sn(c) =

Y¯2 − Y¯1 − d
· · ·
Y¯K − Y¯K−1 − d
n−1
∑n
i=1 I(c1 ≤ µˆ(Vi) ≤ c2)− p0
· · ·
n−1
∑n
i=1 I(cK−1 ≤ µˆ(Vi) ≤ cK)− p0

.
We also define the limiting constraint by S0(c) ≥ 0, where
18
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S0(c) =

µ¯2 − µ¯1 − d
· · ·
µ¯K − µ¯K−1 − d
pr(c1 ≤ µ(Vi) ≤ c2)− p0
· · ·
pr(cK−1 ≤ µ(Vi) ≤ cK)− p0

.
Let c0 be the minimizer of L(c) subject to the constraint S0(c) ≥ 0 and cˆ be the minimizer of
Ln(c) subject to the constraint Sn(c) ≥ 0. Furthermore, we let
cˆ = arg min
c:S0(c)≥
Ln(c) and c = arg min
c:S0(c)≥
L(c).
Under a rather mild condition that the numbers of strata of both stratification rules c˜ and c0 are
the same for some ˜ > 0,
L(c)→ L(c0) = L0, as → 0.
A sufficient condition for the existence of such a ˜ is that the optimal grouping c0 is unique and
the set {(c1, · · · , cK0) | S0(c) ≥ 0} is not contained by a K0 − 1 dimensional hyperplane in RK0 ,
where K0 + 1 is the dimension of the vector c0. Now, since Sn(c)− S(c) = op(1),
pr
[
{c | S0(c) ≥ ε} ⊆ {c | Sn(c) ≥ 0}
]
→ 1, as n→∞,
which implies that
pr {Ln(cˆ) ≤ Ln(cˆε)} → 1 as n→∞.
Furthermore, by the definition of cˆε which minimizes Ln(c) under the constraint S0(c) ≥ ,
Ln(cˆε) ≤ Ln(cε).
From the uniform convergence, for any δ > 0,
pr {Ln(cε) > L(cε) + δ/2} → 0 and pr {L(cˆ)− δ/2 > Ln(cˆ)} → 0 as n→∞.
19
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Therefore, for any δ > 0, there exists an ε0 such that L(cε0) ≤ L0 + δ and
pr(L(cˆ) ≤ L0 + 2δ)
≥ pr {L(cˆ) ≤ Ln(cˆ) + δ/2 ≤ Ln(cˆε0) + δ/2 ≤ Ln(cε0) + δ/2 ≤ L(cε0) + δ}
≥ 1− pr {L(cˆ) > Ln(cˆ) + δ/2} − pr {Ln(cˆ) > Ln(cˆε0)} − pr {Ln(cε0) > L(cε0) + δ/2} → 1,
as n → ∞. It follows that the finite sample optimal stratification scheme minimizes the limit of
the total of intra-stratum predicted error. The estimated stratification scheme approaches that of the
optimal stratification scheme as the sample size goes to infinity.
20
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TABLES and FIGURES
Table 1: Regression model candidates, E(Y |V ) = β′Z, for study ACTG 320, L¯∗ and the complex-
ities ofM∗ (‖β‖0 = the number of nonzero components of βˆ).
Model Candidate independent variables dim(Z) L¯∗ M∗
# covariates ‖βˆ‖0
1 age, sex, CD4 count and log10RNA at baseline and week 4 6 0.415 5 5
2 all baseline covariates plus their first-order interaction terms 78 0.465 12 14
3 all baseline covariates and CD4 and log10RNA at week 4 105 0.414 13 20
plus their first-order interaction terms
4 none 0 0.484 0 0
Table 2: Regression model candidates, log{− logS(t|V )} = log{− logS0(t)} + β′Z, for study
PEACE, L¯∗ and the complexities ofM∗ (‖β‖0 = the number of nonzero components of βˆ).
Model Candidate independent variables dim(Z) L¯∗ M∗
# covariates ‖βˆ‖0
1 age, gender, left ventricular ejection fraction, history of 10 16.919 6 7
myocardial infarction, history of hypertension,
history of diabetes, eGFR, ACE inhibitor treatment
2 variables in Model 1 plus three treatment and eGFR 13 16.903 6 9
interaction terms
3 variables in Model 1 plus their first-order interaction terms 55 16.966 6 9
4 none 0 18.649 0 0
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Figure 1: Stratum-specific point and 95% confidence intervals for the response rates with the Part
II data (denoted by dots) of ACTG 320 with cutoff points cˆ1 = 0.25 and cˆ2 = 0.45.
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Figure 2: The Kaplan-Meier estimate for the time to the composite endpoint with the entire PEACE
dataset.
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Figure 3: Stratum-specific Kaplan-Meier estimates and 95% confidence intervals for RMSTs ob-
tained from Part II data of PEACE study with cˆ1 = 56.5 and cˆ2 = 60.5.
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